Home・Listă Acțiuni・Lantheus Holdings Inc

Lantheus Holdings Inc

Deschisă

SectorSănătate

100.1 -0.15

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

99.98

Maxim

100.47

Indicatori cheie
By Trading Economics
Venit	75M 193M
Vânzări	11M 388M
P/E Medie Sector	24.156 56.597
EPS	1.32
Marjă de profit	49.834
Angajați	1,193
EBITDA	-69M 115M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+5.14% upside

Dividende
By Acuity
Următoarele câștiguri	5 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.5M 6.6B
Deschiderea anterioară	100.25
Închiderea anterioară	100.1

Sentimentul știrilor

By Acuity

60%

40%

273 / 339 Clasament în Healthcare

Lantheus Holdings Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 sept. 2026, 19:46 UTC

Lantheus Holdings Inc. shares are lower today, with no specific news identified. Price action remains flat amid broader market conditions following CPI data release.

10 sept. 2026, 19:16 UTC

Lantheus Holdings Inc. shares are lower today, with no specific news identified. The stock has traded within a routine range since Wednesday's close.

3 sept. 2026, 20:07 UTC

Lantheus Holdings Inc shares are higher during Thursday's session, reflecting a modest gain since Wednesday's close amid routine trading fluctuations.

1 sept. 2026, 19:16 UTC

Lantheus Holdings Inc. shares are trading roughly flat amid no specific news, reflecting minor changes since Monday's close.

20 aug. 2026, 19:36 UTC

Lantheus Holdings Inc. shares are lower, impacted by a decline in the Health Care Supplies sub-sector. The asset remains near its one-month range low.

19 aug. 2026, 23:26 UTC

Lantheus Holdings Inc. is seeing modest gains in after-market trading, with no specific news identified to explain the price movement.

13 aug. 2026, 20:06 UTC

Lantheus Holdings Inc. is moving higher amid overall market gains, despite no specific company news to explain the advance.

12 aug. 2026, 23:36 UTC

Lantheus Holdings Inc. shares declined in after-market trading, remaining below their 20-day moving average amid recent inflation data influencing investor sentiment.

3 aug. 2026, 19:56 UTC

Social Media

News

Event

Lantheus Holdings Inc. to be acquired by Curium for up to $8 billion, offering $102.50 per share plus contingent value rights. Shares rise amid merger news.

31 iul. 2026, 22:01 UTC

Lantheus Holdings Inc shares are lower in after-market hours amid weak trading conditions, remaining below the 20-day moving average and near a one-month low.

30 iul. 2026, 17:31 UTC

Lantheus Holdings Inc is higher during Thursday's session, driven by overall market momentum, despite earlier downward pressure. The S&P 500 Index is also advancing.

29 iul. 2026, 21:42 UTC

Lantheus Holdings Inc is trading lower in after-market hours, influenced by a decline in the broader market and rising oil prices amid geopolitical tensions.

28 iul. 2026, 19:42 UTC

Social Media

Lantheus Holdings is in talks for a $7 billion acquisition by Curium, with shares declining despite the news and reaching a session low earlier.

27 iul. 2026, 22:51 UTC

News

Lantheus Holdings is in talks for a $7 billion acquisition of Curium. Shares are trading lower in after-market hours amid deal evaluations.

24 iul. 2026, 22:01 UTC

Lantheus Holdings Inc is trading lower in after-market hours, moving toward the lower end of its one-month trading range. No specific news was identified.

23 iul. 2026, 23:02 UTC

Lantheus Holdings Inc. shares are lower in after-market trading, continuing a downward trend since Thursday's close, remaining below the 20-day moving average.

22 iul. 2026, 19:06 UTC

Lantheus Holdings Inc shares are lower today, continuing a decline since Tuesday's close. Broader market sentiment is impacted by rising crude oil prices.

21 iul. 2026, 22:46 UTC

Lantheus Holdings Inc shares are trading higher in after-market hours, supported by a broader market rebound, particularly in the tech sector.

20 iul. 2026, 19:46 UTC

Lantheus Holdings Inc. shares are lower today, declining amid rising oil prices above $90 per barrel, contributing to inflationary pressures globally.

Comparație

Modificare preț

Lantheus Holdings Inc Așteptări

Obiectiv de preț

By TipRanks

5.14% sus

Prognoză pe 12 luni

Medie 105.4 USD 5.14%

Maxim 115 USD

Minim 102.5 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLantheus Holdings Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Lantheus Holdings Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

273 / 339 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.